ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-ThalassemiaMaria Domenica Cappellini, Antonis Kattamis, Jeremie H. Estepp et al.|Blood|2024Cited by 14
Early‐onset reduced bone mineral density in patients with pyruvate kinase deficiencyHanny Al‐Samkari, Eduard J. van Beers, Rachael F. Grace et al.|American Journal of Hematology|2023Cited by 4
Long‐term efficacy and safety of mitapivat in non‐transfusion‐dependent α‐ or β‐thalassaemia: An open‐label phase 2 studyKevin H.M. Kuo, Hanny Al‐Samkari, Mark Layton et al.|British Journal of Haematology|2025Cited by 4
Burden of Illness of Alpha- and Beta-Thalassemia: A Qualitative StudySujit Sheth, Kevin H.M. Kuo, Alexander Glaros et al.|Blood|2023Cited by 2
Efficacy of mitapivat in patients with transfusion-dependent alpha-thalassemia: Subgroup analysis from the ENERGIZE-T trialAshutosh Lal, Vip Viprakasit, Andreas Glenthøj et al.|Blood|2025Cited by 2